Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Dihydrotanshinone, a Natural Diterpenoid, Preserves Blood-Retinal Barrier Integrity via P2X7 Receptor.

Tytuł:
Dihydrotanshinone, a Natural Diterpenoid, Preserves Blood-Retinal Barrier Integrity via P2X7 Receptor.
Autorzy:
Fresta CG; Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy.
Caruso G; Department of Drug Sciences, University of Catania, 95125 Catania, Italy.; Oasi Research Institute-IRCCS, 94018 Troina, Italy.
Fidilio A; Department of Drug Sciences, University of Catania, 95125 Catania, Italy.
Platania CBM; Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy.
Musso N; Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy.
Caraci F; Department of Drug Sciences, University of Catania, 95125 Catania, Italy.; Oasi Research Institute-IRCCS, 94018 Troina, Italy.
Drago F; Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy.; Center for Research in Ocular Pharmacology-CERFO, University of Catania, 95125 Catania, Italy.
Bucolo C; Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy.; Center for Research in Ocular Pharmacology-CERFO, University of Catania, 95125 Catania, Italy.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2020 Dec 06; Vol. 21 (23). Date of Electronic Publication: 2020 Dec 06.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
Blood-Retinal Barrier/*drug effects
Furans/*pharmacology
Phenanthrenes/*pharmacology
Purinergic P2X Receptor Antagonists/*pharmacology
Receptors, Purinergic P2X7/*metabolism
Adenosine Triphosphate/analogs & derivatives ; Adenosine Triphosphate/toxicity ; Astrocytes/drug effects ; Astrocytes/metabolism ; Binding Sites ; Blood-Retinal Barrier/cytology ; Blood-Retinal Barrier/metabolism ; Capillary Permeability ; Cell Line ; Connexin 43/metabolism ; Cytokines/metabolism ; Cytoprotection ; Endothelial Cells/drug effects ; Endothelial Cells/metabolism ; Furans/chemistry ; Humans ; Pericytes/drug effects ; Pericytes/metabolism ; Phenanthrenes/chemistry ; Protein Binding ; Purinergic P2X Receptor Agonists/toxicity ; Purinergic P2X Receptor Antagonists/chemistry ; Quinones ; Reactive Oxygen Species/metabolism ; Receptors, Purinergic P2X7/chemistry
References:
Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3758-63. (PMID: 20130277)
J Ophthalmic Vis Res. 2014 Jul-Sep;9(3):362-73. (PMID: 25667739)
Am J Physiol Cell Physiol. 2011 Nov;301(5):C1213-23. (PMID: 21832250)
Drugs Context. 2018 Aug 13;7:212532. (PMID: 30181760)
Front Pharmacol. 2018 Feb 01;9:39. (PMID: 29449813)
J Ophthalmol. 2017;2017:9402198. (PMID: 28680705)
Glia. 2014 Sep;62(9):1486-501. (PMID: 24839011)
Pathophysiology. 2017 Dec;24(4):229-241. (PMID: 28732591)
BMC Bioinformatics. 2017 Nov 29;18(1):529. (PMID: 29187165)
Free Radic Biol Med. 2010 May 1;48(9):1121-32. (PMID: 20083193)
Biochem Pharmacol. 2017 Aug 15;138:130-139. (PMID: 28479300)
Expert Opin Investig Drugs. 2011 Jul;20(7):897-915. (PMID: 21510825)
Br J Pharmacol. 2013 Oct;170(3):624-40. (PMID: 23889535)
World J Diabetes. 2014 Apr 15;5(2):141-5. (PMID: 24748927)
Int J Mol Sci. 2020 Feb 27;21(5):. (PMID: 32121029)
Sci Rep. 2016 Jul 06;6:29393. (PMID: 27381080)
Exp Cell Res. 2017 Sep 1;358(1):39-44. (PMID: 28372972)
J Ocul Pharmacol Ther. 2020 Jan/Feb;36(1):30-41. (PMID: 31140899)
Biochem Pharmacol. 2019 Oct;168:249-258. (PMID: 31302133)
Biochem Pharmacol. 2020 May;175:113908. (PMID: 32171729)
Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5594-5603. (PMID: 29084332)
Exp Diabetes Res. 2010;2010:247861. (PMID: 21052489)
Vision (Basel). 2018 Sep;2(3):. (PMID: 30288454)
Mol Vis. 2009 Jul 25;15:1418-28. (PMID: 19641635)
PLoS One. 2015 May 04;10(5):e0125111. (PMID: 25938443)
Biochem Pharmacol. 2020 Oct;180:114199. (PMID: 32798466)
Pflugers Arch. 2017 Jan;469(1):55-67. (PMID: 27624415)
Front Pharmacol. 2017 Mar 16;8:123. (PMID: 28360855)
Biochem Pharmacol. 2017 Oct 15;142:145-154. (PMID: 28651842)
J Clin Invest. 1996 Jun 15;97(12):2883-90. (PMID: 8675702)
Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2408-13. (PMID: 11527957)
Circ Res. 2002 Mar 22;90(5):570-7. (PMID: 11909821)
Methods Mol Biol. 2011;686:133-48. (PMID: 21082369)
Sci Rep. 2019 Dec 13;9(1):19059. (PMID: 31836806)
Int J Retina Vitreous. 2019 Oct 1;5:29. (PMID: 31583119)
Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10836-41. (PMID: 10485912)
Cell. 2019 Oct 17;179(3):659-670.e13. (PMID: 31587896)
J Physiol. 2003 Sep 15;551(Pt 3):787-99. (PMID: 12876212)
Diabet Med. 2002 May;19(5):371-6. (PMID: 12027924)
Clin Exp Ophthalmol. 2016 May;44(4):260-77. (PMID: 26716602)
Int J Cancer. 2019 Aug 15;145(4):1068-1082. (PMID: 30761524)
Arch Ophthalmol. 2000 Oct;118(10):1364-9. (PMID: 11030818)
Front Pharmacol. 2019 Jun 21;10:693. (PMID: 31293421)
Mol Biol Cell. 2006 Apr;17(4):1922-32. (PMID: 16436508)
Antioxid Redox Signal. 2010 Jun 15;12(12):1431-70. (PMID: 19803744)
Lancet. 1994 Apr 2;343(8901):831-6. (PMID: 7908081)
Invest Ophthalmol Vis Sci. 2013 Oct 03;54(10):6518-25. (PMID: 24008412)
Curr Eye Res. 2014 Feb;39(2):105-19. (PMID: 24144321)
Epilepsia. 2017 Jul;58 Suppl 3:27-38. (PMID: 28675563)
Antioxidants (Basel). 2019 Aug 06;8(8):. (PMID: 31390749)
J Biol Chem. 2004 Oct 22;279(43):44785-94. (PMID: 15292177)
J Ophthalmol. 2015;2015:605946. (PMID: 25821590)
Acta Diabetol. 2019 Sep;56(9):1031-1036. (PMID: 30982154)
Biochem Pharmacol. 2020 Aug;178:114110. (PMID: 32569630)
J Cell Physiol. 2017 May;232(5):1079-1085. (PMID: 27486932)
J Cell Sci. 2015 Dec 15;128(24):4615-28. (PMID: 26542019)
Future Med Chem. 2019 Jul;11(13):1523-1536. (PMID: 31469335)
Pharmacol Res. 2019 Apr;142:102-114. (PMID: 30794925)
Ophthalmic Epidemiol. 2007 Jul-Aug;14(4):179-83. (PMID: 17896294)
Med Sci Monit. 2020 Feb 29;26:e920738. (PMID: 32112706)
Saudi J Ophthalmol. 2018 Oct-Dec;32(4):318-323. (PMID: 30581303)
J Med Chem. 2004 Jan 15;47(2):337-44. (PMID: 14711306)
Micromachines (Basel). 2020 Jun 15;11(6):. (PMID: 32549277)
Eur J Ophthalmol. 2011;21 Suppl 6:S3-9. (PMID: 23264323)
Sci Rep. 2019 Sep 19;9(1):13587. (PMID: 31537874)
Diabetes. 2007 Jan;56(1):224-30. (PMID: 17192486)
J Mol Histol. 2008 Apr;39(2):243-9. (PMID: 18165914)
Eye (Lond). 2018 Jul;32(7):1157-1163. (PMID: 29520046)
J Biochem Mol Biol. 2006 Sep 30;39(5):469-78. (PMID: 17002866)
Nat Commun. 2016 Feb 15;7:10555. (PMID: 26877061)
Sci Rep. 2018 Sep 20;8(1):14117. (PMID: 30237412)
Br J Pharmacol. 2000 Jul;130(5):963-74. (PMID: 10882379)
Exp Eye Res. 2012 Mar;96(1):181-90. (PMID: 22200486)
Int J Ophthalmol. 2019 Feb 18;12(2):302-311. (PMID: 30809489)
Oxid Med Cell Longev. 2017;2017:3940241. (PMID: 29410732)
Purinergic Signal. 2018 Dec;14(4):471-484. (PMID: 30415294)
Exp Eye Res. 2013 Oct;115:162-71. (PMID: 23891860)
Vision Res. 2017 Oct;139:123-137. (PMID: 28619516)
J Pharmacol Sci. 2018 Dec;138(4):219-232. (PMID: 30503676)
Am J Physiol Cell Physiol. 2005 Mar;288(3):C568-76. (PMID: 15496477)
J Diabetes Res. 2014;2014:790902. (PMID: 25610879)
JCI Insight. 2019 Mar 19;5:. (PMID: 30888334)
J Diabetes Res. 2019 Aug 14;2019:8562408. (PMID: 31511825)
Sci Rep. 2015 Nov 10;5:16478. (PMID: 26553968)
Front Pharmacol. 2018 Feb 01;9:30. (PMID: 29449810)
Exp Eye Res. 2014 Oct;127:270-9. (PMID: 25151301)
Grant Information:
PRIN 2015JXE7E8 Ministry of Education, University and Research (MIUR); E37H18000340006 Italian Ministry of Economic Development (MISE) PON-Innovative PhD Program XXXIII; Linea Intervento 2, University of Catania PIACERI 2020/2022
Contributed Indexing:
Keywords: blood-retinal barrier; diabetic retinopathy; endothelial cells; inflammation; oxidative stress; purinergic P2X7 receptor
Substance Nomenclature:
0 (Connexin 43)
0 (Cytokines)
0 (Furans)
0 (Phenanthrenes)
0 (Purinergic P2X Receptor Agonists)
0 (Purinergic P2X Receptor Antagonists)
0 (Quinones)
0 (Reactive Oxygen Species)
0 (Receptors, Purinergic P2X7)
4P5DXU1F8Q (3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate)
562G9360V6 (dihydrotanshinone I)
8L70Q75FXE (Adenosine Triphosphate)
Entry Date(s):
Date Created: 20201209 Date Completed: 20210304 Latest Revision: 20211204
Update Code:
20240104
PubMed Central ID:
PMC7730037
DOI:
10.3390/ijms21239305
PMID:
33291318
Czasopismo naukowe
Activation of P2X7 signaling, due to high glucose levels, leads to blood retinal barrier (BRB) breakdown, which is a hallmark of diabetic retinopathy (DR). Furthermore, several studies report that high glucose (HG) conditions and the related activation of the P2X7 receptor (P2X7R) lead to the over-expression of pro-inflammatory markers. In order to identify novel P2X7R antagonists, we carried out virtual screening on a focused compound dataset, including indole derivatives and natural compounds such as caffeic acid phenethyl ester derivatives, flavonoids, and diterpenoids. Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) rescoring and structural fingerprint clustering of docking poses from virtual screening highlighted that the diterpenoid dihydrotanshinone (DHTS) clustered with the well-known P2X7R antagonist JNJ47965567. A human-based in vitro BRB model made of retinal pericytes, astrocytes, and endothelial cells was used to assess the potential protective effect of DHTS against HG and 2'(3')-O-(4-Benzoylbenzoyl)adenosine-5'-triphosphate (BzATP), a P2X7R agonist, insult. We found that HG/BzATP exposure generated BRB breakdown by enhancing barrier permeability (trans-endothelial electrical resistance (TEER)) and reducing the levels of ZO-1 and VE-cadherin junction proteins as well as of the Cx-43 mRNA expression levels. Furthermore, HG levels and P2X7R agonist treatment led to increased expression of pro-inflammatory mediators (TLR-4, IL-1β, IL-6, TNF-α, and IL-8) and other molecular markers (P2X7R, VEGF-A, and ICAM-1), along with enhanced production of reactive oxygen species. Treatment with DHTS preserved the BRB integrity from HG/BzATP damage. The protective effects of DHTS were also compared to the validated P2X7R antagonist, JNJ47965567. In conclusion, we provided new findings pointing out the therapeutic potential of DHTS, which is an inhibitor of P2X7R, in terms of preventing and/or counteracting the BRB dysfunctions elicited by HG conditions.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies